PMID- 32347523
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20240329
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 37
IP  - 6
DP  - 2020 Jun
TI  - Alternative Regimens of Neuraminidase Inhibitors for Therapy of Hospitalized 
      Adults with Influenza: A Systematic Review of Randomized Controlled Trials.
PG  - 2646-2666
LID - 10.1007/s12325-020-01347-5 [doi]
AB  - INTRODUCTION: Influenza in hospitalized intensive care unit (ICU) patients with 
      respiratory failure is associated with 25% mortality, despite timely oseltamivir 
      treatment. A systematic review of randomized controlled trials (RCTs) was 
      conducted to evaluate the efficacy and safety of alternative neuraminidase 
      inhibitor (NAI) regimens compared to standard of care in patients hospitalized 
      for H1N1, H3N2, or B influenza. METHODS: The Cochrane collaboration searching 
      methods were followed in Cochrane Library, PubMed, and Web of Science databases 
      (2009-2019). Eligibility criteria were RCTs comparing different regimens of NAIs 
      in hospitalized patients (at least 1 year old) for clinically diagnosed influenza 
      (H1N1, H3N2, or B). Pre-defined endpoints were time to clinical resolution 
      (TTCR), overall mortality, hospital discharge, viral clearance, drug-related 
      adverse events (AEs), and serious adverse events. RESULTS: Seven trials (1579 
      patients) were included. Two trials compared two regimens of oral oseltamivir 
      therapy, and one trial compared two regimens of intravenous zanamivir therapy vs 
      oral oseltamivir therapy. Four trials focused on intravenous peramivir therapy: 
      two trials compared two different regimens and two trials compared two different 
      regimens vs oral oseltamivir therapy. Overall, the different regimens were well 
      tolerated, with no significant differences in AEs; nonetheless non-significant 
      differences were reported among different regimens regarding TTCR, mortality, and 
      viral clearance. CONCLUSION: Higher compared to standard doses of NAIs or 
      systemic peramivir therapy compared to oral oseltamivir therapy did not 
      demonstrate benefit.
FAU - Tejada, Sofia
AU  - Tejada S
AD  - Clinical Research/Epidemiology in Pneumonia and Sepsis (CRIPS), Vall d'Hebron 
      Institut of Research (VHIR), Barcelona, Spain. stmagraner@gmail.com.
AD  - CIBER de Enfermedades Respiratorias, CIBERES, Instituto de Salud Carlos III, 
      Barcelona, Spain. stmagraner@gmail.com.
FAU - Campogiani, Laura
AU  - Campogiani L
AD  - Clinical Infectious Diseases, Department of System Medicine, Tor Vergata 
      University, Rome, Italy.
FAU - Sole-Lleonart, Candela
AU  - Sole-Lleonart C
AD  - Critical Care Department, Hospital Universitari de Vic, Barcelona, Spain.
FAU - Rello, Jordi
AU  - Rello J
AD  - Clinical Research/Epidemiology in Pneumonia and Sepsis (CRIPS), Vall d'Hebron 
      Institut of Research (VHIR), Barcelona, Spain.
AD  - CIBER de Enfermedades Respiratorias, CIBERES, Instituto de Salud Carlos III, 
      Barcelona, Spain.
AD  - Anesthesiology and Critical Care Division, CHU Nimes, University 
      Montpellier-Nimes, Nimes, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200428
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Antiviral Agents)
RN  - EC 3.2.1.18 (Neuraminidase)
MH  - Adult
MH  - Antiviral Agents/*pharmacology
MH  - Clinical Protocols
MH  - Critical Care/*methods
MH  - Humans
MH  - Influenza, Human/*drug therapy
MH  - Neuraminidase/*antagonists & inhibitors
MH  - Randomized Controlled Trials as Topic
MH  - Respiratory Insufficiency/therapy
PMC - PMC7187665
OTO - NOTNLM
OT  - Adverse events
OT  - Influenza
OT  - Mortality
OT  - Neuraminidase inhibitors
OT  - Oseltamivir
OT  - Peramivir
OT  - Zanamivir
EDAT- 2020/04/30 06:00
MHDA- 2021/02/16 06:00
PMCR- 2020/04/28
CRDT- 2020/04/30 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/28 00:00 [pmc-release]
AID - 10.1007/s12325-020-01347-5 [pii]
AID - 1347 [pii]
AID - 10.1007/s12325-020-01347-5 [doi]
PST - ppublish
SO  - Adv Ther. 2020 Jun;37(6):2646-2666. doi: 10.1007/s12325-020-01347-5. Epub 2020 
      Apr 28.